Type your tag names separated by a space and hit enter




Trade Name(s)

  • Rapivab

Ther. Class.

Pharm. Class.
neuraminidase inhibitors


Treatment of acute uncomplicated influenza in patients ≥18 yr who have had symptoms for two days or less.


Inhibits the enzyme neuraminidase, which may alter virus particle aggregation and release.

Therapeutic Effect(s):

Reduced duration or prevention of flu-related symptoms.


Absorption: IV administration results in complete bioavailability.

Distribution: Unknown.

Metabolism and Excretion: Mostly eliminated unchanged by kidneys (> 90%).

Half-life: 20.8 hr.

TIME/ACTION PROFILE (blood levels)

IVrapidend of infusionunknown


Contraindicated in:

  • Hypersensitivity.

Use Cautiously in:

  • Renal impairment (dose ↓ required for CCr <50 mL/min)
  • Geri: Consider age-related ↓ in hepatic, renal, cardiac function, concurrent diseases and drug therapy;
  • OB: Use only if clearly needed;
  • Lactation:Consider benefits of breastfeeding, need for peramivir, and potential for adverse effects;
  • Pedi: Safety and effectiveness not established.

Adverse Reactions/Side Effects

CNS: insomnia, neuropsychiatric events

CV: hypertension

GI: constipation



* CAPITALS indicate life-threatening.
Underline indicate most frequent.



Avoid use of live attenuated influenza vaccine within 2 wk prior and 48 hr after peramivir; interference may occur.


IV: (Adults) 600 mg.

Renal Impairment
IV: (Adults) CCr 30–49 mL/min– 200 mg, CCr 10–29 mL/min– 100 mg.


Solution for injection: 10 mg/mL


  • Assess for signs and symptoms of influenza (fever, dyspnea, tachypnea, tachycardia, hypotension) prior to and at least daily during therapy. Patient must be symptomatic for no more than 2 days to receive peramivir.
  • Monitor for signs of neuropsychiatric symptoms (hallucinations, delirium, abnormal behavior) during therapy.
  • Assess patient for skin rash during therapy. Monitor closely and treat symptomatically.

Lab Test Considerations:

May cause ↑ serum ALT, AST, glucose, creatine phosphokinase, and ↓ neutrophils.

Potential Diagnoses


IV Administration

  • Intermittent Infusion: Diluent: 0.9% NaCl or 0.45% NaCl, D5, or LR to a maximum volume of 100 mL. Solution is clear and colorless; do not administer solution that is discolored or contains a precipitate. Upon dilution, administer immediately or refrigerate up to 24 hrs; discard after 24 hrs. Allow to reach room temperature prior to administration. Discard unused portion of single use vial.
  • Rate: Infuse over 15 to 30 min.
  • Y-Site IncompatibilityDo not administer simultaneously with any other medication.

Patient/Family Teaching

  • Explain purpose of peramivir to patient.
  • Advise patient to notify health care professional if signs and symptoms of anaphylaxis or rash, or neuropsychiatric symptoms occur.
  • Advise female patient to notify health care professional if pregnancy is planned or suspected or if breastfeeding.

Evaluation/Desired Outcomes

Resolution of sign and symptoms of influenza.

peramivir is a sample topic from the Davis's Drug Guide.

To view other topics, please or purchase a subscription.

Nursing Central is the award-winning, complete mobile solution for nurses and students. Look up information on diseases, tests, and procedures; then consult the database with 5,000+ drugs or refer to 65,000+ dictionary terms. Learn more.


Quiring, Courtney, et al. "Peramivir." Davis's Drug Guide, 16th ed., F.A. Davis Company, 2019. Nursing Central, nursing.unboundmedicine.com/nursingcentral/view/Davis-Drug-Guide/110183/all/peramivir.
Quiring C, Sanoski CA, Vallerand AH. Peramivir. Davis's Drug Guide. 16th ed. F.A. Davis Company; 2019. https://nursing.unboundmedicine.com/nursingcentral/view/Davis-Drug-Guide/110183/all/peramivir. Accessed April 25, 2019.
Quiring, C., Sanoski, C. A., & Vallerand, A. H. (2019). Peramivir. In Davis's Drug Guide. Available from https://nursing.unboundmedicine.com/nursingcentral/view/Davis-Drug-Guide/110183/all/peramivir
Quiring C, Sanoski CA, Vallerand AH. Peramivir [Internet]. In: Davis's Drug Guide. F.A. Davis Company; 2019. [cited 2019 April 25]. Available from: https://nursing.unboundmedicine.com/nursingcentral/view/Davis-Drug-Guide/110183/all/peramivir.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC T1 - peramivir ID - 110183 A1 - Quiring,Courtney, AU - Sanoski,Cynthia A, AU - Vallerand,April Hazard, BT - Davis's Drug Guide UR - https://nursing.unboundmedicine.com/nursingcentral/view/Davis-Drug-Guide/110183/all/peramivir PB - F.A. Davis Company ET - 16 DB - Nursing Central DP - Unbound Medicine ER -